Drug intelligence / Profile preview

bifidobacterium animalis subsp. lactis R7970

Development stage: Unknown
Lead developer: Tongji Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium animalis subsp. lactis R7970 is a specific strain of probiotic bacteria being investigated for its therapeutic potential. It is currently the subject of a Phase 1/2 clinical trial in China to evaluate its efficacy and safety in the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). [2, 3] The rationale for its use in kidney disease stems from the gut-kidney axis theory, which suggests that modulating the gut microbiome can impact systemic health. [1] Probiotics like B. animalis subsp. lactis may help by altering the gut microbiota, which can in turn reduce the production of uremic toxins and systemic inflammation, factors implicated in the progression of chronic kidney disease. [1, 4] In the trial, it is administered orally as a powder in a sachet. [2, 3]

Targets

PLG (Plasminogen)

Beyond the preview

Go deeper on bifidobacterium animalis subsp. lactis R7970.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium animalis subsp. lactis R7970.

Explore the full profile